Zimmer Biomet (NYSE:ZBH) Upgraded by Wall Street Zen to Buy Rating

Wall Street Zen upgraded shares of Zimmer Biomet (NYSE:ZBH) from a hold rating to a buy rating in a report published on Saturday.

Several other analysts also recently weighed in on ZBH. Citigroup cut their price target on Zimmer Biomet from $98.00 to $95.00 and set a “neutral” rating on the stock in a research note on Wednesday, April 29th. Weiss Ratings upgraded Zimmer Biomet from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Tuesday, April 7th. William Blair started coverage on Zimmer Biomet in a research note on Friday, February 20th. They set a “market perform” rating on the stock. Citizens Jmp cut their target price on Zimmer Biomet from $120.00 to $105.00 and set a “market outperform” rating on the stock in a research note on Wednesday, April 29th. Finally, Leerink Partners started coverage on Zimmer Biomet in a research note on Monday, April 13th. They set a “hold” rating and a $101.00 target price on the stock. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, twelve have assigned a Hold rating and three have given a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $102.80.

Zimmer Biomet Stock Performance

Zimmer Biomet stock opened at $82.24 on Friday. The company has a quick ratio of 0.95, a current ratio of 1.73 and a debt-to-equity ratio of 0.50. The company has a market capitalization of $15.91 billion, a P/E ratio of 21.36, a PEG ratio of 1.90 and a beta of 0.48. The stock’s 50 day moving average is $91.56 and its 200 day moving average is $92.31. Zimmer Biomet has a twelve month low of $79.83 and a twelve month high of $108.29.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings results on Tuesday, April 28th. The medical equipment provider reported $2.09 earnings per share for the quarter, topping the consensus estimate of $1.86 by $0.23. The company had revenue of $2.09 billion for the quarter, compared to the consensus estimate of $2.07 billion. Zimmer Biomet had a return on equity of 13.24% and a net margin of 9.05%.The firm’s quarterly revenue was up 9.3% compared to the same quarter last year. During the same quarter in the prior year, the business posted $1.81 EPS. Zimmer Biomet has set its FY 2026 guidance at 8.400-8.550 EPS. On average, equities research analysts predict that Zimmer Biomet will post 8.47 earnings per share for the current fiscal year.

Zimmer Biomet Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Thursday, April 30th. Stockholders of record on Tuesday, March 31st were paid a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a dividend yield of 1.2%. The ex-dividend date was Tuesday, March 31st. Zimmer Biomet’s dividend payout ratio (DPR) is 24.94%.

Insider Activity

In other news, SVP Lori Winkler sold 2,650 shares of the firm’s stock in a transaction on Thursday, March 12th. The stock was sold at an average price of $94.66, for a total value of $250,849.00. Following the transaction, the senior vice president directly owned 10,224 shares in the company, valued at $967,803.84. This trade represents a 20.58% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. 1.28% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Zimmer Biomet

A number of institutional investors and hedge funds have recently modified their holdings of the company. Dodge & Cox boosted its stake in shares of Zimmer Biomet by 1.3% in the 4th quarter. Dodge & Cox now owns 23,506,849 shares of the medical equipment provider’s stock worth $2,113,736,000 after buying an additional 290,676 shares during the last quarter. Vanguard Group Inc. boosted its stake in shares of Zimmer Biomet by 0.8% in the 4th quarter. Vanguard Group Inc. now owns 23,483,741 shares of the medical equipment provider’s stock worth $2,111,658,000 after buying an additional 192,517 shares during the last quarter. State Street Corp boosted its stake in shares of Zimmer Biomet by 2.3% in the 4th quarter. State Street Corp now owns 8,826,974 shares of the medical equipment provider’s stock worth $795,814,000 after buying an additional 195,214 shares during the last quarter. Capital International Investors boosted its stake in shares of Zimmer Biomet by 11.5% in the 3rd quarter. Capital International Investors now owns 7,550,754 shares of the medical equipment provider’s stock worth $743,749,000 after buying an additional 778,467 shares during the last quarter. Finally, Franklin Resources Inc. boosted its stake in shares of Zimmer Biomet by 43.2% in the 4th quarter. Franklin Resources Inc. now owns 6,685,987 shares of the medical equipment provider’s stock worth $601,204,000 after buying an additional 2,017,857 shares during the last quarter. 88.89% of the stock is currently owned by hedge funds and other institutional investors.

Zimmer Biomet Company Profile

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.